Pulse Biosciences Q3 2023 Earnings Report
Key Takeaways
Pulse Biosciences reported a GAAP net loss of $10.6 million for the third quarter of 2023, compared to a $18.0 million loss in the same period of the previous year. The company's cash and cash equivalents totaled $50.4 million as of September 30, 2023. They are on track to file a 510(k) submission for clearance for their cardiac ablation clamp and initiate the cardiac ablation catheter first-in-human study between December 2023 and end of first quarter 2024.
Advanced cardiac device development with CellFX nsPFA technology demonstrating potential for atrial fibrillation treatment.
CellFX nsPFA is demonstrating the ability to safely and effectively treat benign thyroid nodules.
Addition of Dr. Niv Ad to the leadership team.
On track to file a 510(k) submission for clearance for cardiac ablation clamp and initiate cardiac ablation catheter first-in-human study between December 2023 and end of first quarter 2024.